Study in peopleStudy in peopleResearchers gave ibogaine to people, or followed people who took it, and measured what changed.3 min read

Brown & Alper (2018): opioid detox and drug use over 12 months at two clinics in Mexico

In short

Two US researchers set out to do something that, by their account, no one had published: follow people for a year after ibogaine. They followed 30 people dependent on opioids, mostly oxycodone or heroin, treated at two clinics in Baja California, Mexico; 29 of them had already tried other treatments. Withdrawal dropped by more than half. In phone interviews at one, three, six, nine and twelve months, drug use stayed well below where it started. Half reported no opioids in the first month; at a year, 7 of the 30 did. There was no comparison group, many missed some interviews, and it all rests on what people reported.

Card updated 10 October 2026: first publication

This page summarizes what formal research has documented. It is not everything known about iboga: the Bwiti tradition and decades of clinical experience are knowledge too. Before you read: what science sees, and what it can't.

Citation: Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36.
Read the original: DOI
Access: Free to read
At a glance: Prospective observational study · People with opioid use disorder · 30 participants · Two clinics in Mexico

What it says

The researchers followed 30 people with opioid use disorder who chose treatment at two ibogaine clinics in Mexico, and measured them before treatment and at intervals over the following year. Withdrawal scores fell by roughly half within about three days. One month after treatment, half of the participants reported no opioid use. At twelve months, about one in four did. The authors report no clinically significant cardiovascular events. Taken together, the results show a strong early effect followed, for many people, by gradual relapse.

Limits

Abstinence was self-reported, not confirmed by drug tests. There was no comparison group. The participants had already tried other treatments without lasting success: that makes them a hard-to-treat group, but also a self-selected one, so the results may not apply to everyone. Thirty people is a small sample for estimating relapse over a year.

How it fits

It is one of the few studies with a full year of follow-up, and its honest relapse curve is why it sits on our hub. It shows why the weeks and months after treatment matter so much.

Topics: Ibogaine research: what the science says
This summary is information, not medical advice. How we use sources

Reviewed by the IbogaQuest medical team · Last reviewed 10 October 2026

Was this summary helpful?